GYRE

Gyre Therapeutics Inc

4.55

Oct 30 • 3:59 PM ET -1.86 (-28.94%)

4.71

Aftermarket • 7:30 PM ET +0.16 (3.40%)

Healthcare Biotechnology USA Small NASD

Oct 30, 7:31 PMNo clear catalyst identified for GYRE 29% regular-hours drop

Peers: GALT IVA SGMT ALT AVLN MDGL PLRX AAPG VCRE MTVA

| Held by: VTI VXF IWM SCHA VTWO IWO IWN SCHB EES VTWG

Scroll to Statements

Index	RUT
Market Cap	482.98M
Enterprise Value	468.59M
Income	-18.47M
Sales	119.38M
Book/sh	1.02
Cash/sh	0.71
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jan 13, 2023
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	625
IPO	Apr 12, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	4.05
P/B	4.48
P/C	6.46
P/FCF	-
EV/EBITDA	-
EV/Sales	3.93
Quick Ratio	3.66
Current Ratio	4.26
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-0.20
EPS next Y	-0.23
EPS next Q	-0.12
EPS this Y	-2100.00%
EPS next Y	41.25%
EPS next 5Y	-
EPS past 3/5Y	-63.33% -
Sales past 3/5Y	4.46% 40.96%
EPS Y/Y TTM	-494.61%
Sales Y/Y TTM	16.83%
EPS Q/Q	-5368.18%
Sales Q/Q	8.72%
Earnings	Aug 07 BMO
EPS/Sales Surpr.	-111.64% 9.87%

Insider Own	77.69%
Insider Trans	-0.18%
Inst Own	4.65%
Inst Trans	9.22%
ROA	-9.89%
ROE	-15.66%
ROIC	-13.15%
Gross Margin	94.30%
Oper. Margin	-11.41%
Profit Margin	-15.47%
SMA20	-29.01%
SMA50	-32.34%
SMA200	-34.82%
Trades

Shs Outstand	106.03M
Shs Float	23.65M
Short Float	8.15%
Short Ratio	15.81
Short Interest	1.93M
52W High	9.14 -50.16%
52W Low	5.44 -16.27%
Volatility	15.21% 6.85%
ATR (14)	0.48
RSI (14)	29.50
Beta	2.00
Rel Volume	3.23
Avg Volume	121.97K
Volume	394,091

Perf Week	-22.14%
Perf Month	-34.93%
Perf Quarter	-25.45%
Perf Half Y	-41.60%
Perf YTD	-35.48%
Perf Year	-40.46%
Perf 3Y	-40.61%
Perf 5Y	-43.28%
Perf 10Y	-82.96%
Recom	1.00
Target Price	18.67
Prev Close	6.41
Price	4.55
Change %	-28.94%

Consensus

Strong Buy

Avg. Price Target

$18.67

Implied Upside

+309.9%

Analysts11incl. previous ratings

Rating Distribution11 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 10, 2025	Initiated	JJefferies	Buy	$16	+251.3%
Aug 26, 2025	Initiated	HH.C. Wainwright	Buy	$18	+295.2%
Mar 11, 2025	Initiated	NNoble Capital Markets	Outperform
Apr 29, 2021	Resumed	SStephens	Overweight	$18 → $19	+317.1%
Feb 10, 2021	Initiated	PPiper Sandler	Overweight	$15	+229.3%
May 21, 2020	Initiated	RRaymond James	Outperform	$20	+339.1%
Jan 04, 2019	Initiated	OOppenheimer	Outperform	$24	+426.9%
Feb 12, 2018	Reiterated	BB. Riley FBR, Inc.	Buy	$19 → $49	+975.7%
Feb 09, 2018	Reiterated	CChardan Capital Markets	Buy	$37.50 → $75	+1,546.5%
Feb 09, 2018	Reiterated	CChardan Capital Markets	Buy	$10 → $75	+1,546.5%
Dec 08, 2017	Initiated	BB. Riley FBR, Inc.	Buy	$19	+317.1%
Jun 12, 2017	Initiated	CChardan Capital Markets	Buy	$10	+119.5%
Jun 06, 2017	Initiated	LLadenburg Thalmann	Buy	$11	+141.5%
Jun 30, 2016	Initiated	RRodman & Renshaw	Buy	$3.50	-23.2%

Sep-03-26 07:00AM	Gyre Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-07-26 07:00AM	Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update (GlobeNewswire)
Jul-16-26 04:05PM	Gyre Therapeutics Appoints Three New Members to its Board of Directors (GlobeNewswire) -5.76%
May-12-26 04:05PM	Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment (GlobeNewswire)
May-07-26 06:00AM	Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update (GlobeNewswire) -12.06%
08:47AM	Loading…
May-04-26 08:47AM	Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company (GlobeNewswire)
Mar-17-26 07:00AM	Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment (GlobeNewswire)
Mar-12-26 06:00AM	Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) -6.30%
Mar-10-26 08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-09-26 05:15PM	Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.84%
Mar-03-26 08:23AM	Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction (TipRanks) -9.82%
Feb-24-26 07:30PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jan-05-26 07:00AM	Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting (GlobeNewswire) +16.30%
Nov-07-25 07:10AM	Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates (Zacks)
06:00AM	Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update (GlobeNewswire)
06:05PM	Loading…
Oct-29-25 06:05PM	Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-17-25 05:29AM	New Strong Sell Stocks for Oct. 17th (Zacks) -5.03%
Oct-15-25 07:00AM	Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis (GlobeNewswire) +10.74%
Oct-14-25 07:00AM	Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD-The Liver Meeting 2025 (GlobeNewswire)
Oct-09-25 10:13AM	Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? (Zacks)
Sep-05-25 04:05PM	Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-22-25 07:00AM	Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors (GlobeNewswire) +8.34%
Aug-11-25 04:01PM	Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update (GlobeNewswire) +6.93%
Aug-07-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-04-25 05:50PM	Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +5.56%
Jun-10-25 07:00AM	Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China (GlobeNewswire) +5.88%
May-29-25 11:34PM	Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials (Insider Monkey)
04:01PM	Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-22-25 08:57PM	Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock (GlobeNewswire) +8.10% -22.57%
04:02PM	Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock (GlobeNewswire)
04:01PM	Loading…
04:01PM	Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China (GlobeNewswire)
May-09-25 06:00AM	Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 09:15AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-01-25 08:25AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Mar-31-25 07:00AM	Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications (GlobeNewswire) -15.26%
Mar-27-25 07:00AM	Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology (GlobeNewswire)
Mar-21-25 09:14AM	Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines (SeekingAlpha)
Mar-17-25 04:15PM	Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -30.21%
Jan-06-25 07:00AM	Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors (GlobeNewswire) -9.82%
Nov-13-24 06:00AM	Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update (GlobeNewswire) -9.56%
Oct-22-24 04:05PM	Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis (GlobeNewswire)
Oct-01-24 04:05PM	Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference (GlobeNewswire)
Sep-04-24 04:05PM	Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 06:00AM	Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update (GlobeNewswire)
Aug-09-24 07:00AM	Gyre Therapeutics to Present at Sidoti Virtual Investor Conference (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire)
Jul-02-24 04:05PM	Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia (GlobeNewswire)
Jun-18-24 04:05PM	Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology (GlobeNewswire) -6.33%
May-30-24 04:05PM	Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire) +9.13%
May-28-24 04:05PM	Gyre Therapeutics Announces Expected Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) -15.35%
May-09-24 04:10PM	Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-28-24 05:32AM	Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress (GuruFocus.com)
Mar-26-24 06:32AM	Gyre Therapeutics Posts Loss In 2023 (RTT News)
06:00AM	Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-24 07:00AM	Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum (GlobeNewswire)
Dec-15-23 09:04AM	Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding (PR Newswire) +9.91%
Nov-13-23 07:00AM	Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting (GlobeNewswire)
Oct-30-23 12:00PM	Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split (GlobeNewswire)
Aug-23-23 12:36PM	Is Catalyst Biosciences (CBIO) Significantly Overvalued? (GuruFocus.com) +11.72%
Apr-03-23 09:01AM	Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months (Simply Wall St.)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Feb-28-23 08:00AM	Catalyst Biosciences Provides Corporate Update (GlobeNewswire) +23.75%
Dec-27-22 07:00AM	Catalyst Biosciences Completes First Steps in Reverse Merger Plan (GlobeNewswire)
Nov-16-22 05:05AM	Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021) (Simply Wall St.)
Sep-19-22 09:43AM	Bullish insiders at Catalyst Biosciences, Inc. (NASDAQ:CBIO) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Sep-01-22 04:05PM	Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share (GlobeNewswire)
Aug-25-22 08:00AM	Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share (GlobeNewswire)
Aug-23-22 07:11AM	Catalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years ago (Simply Wall St.)
Aug-19-22 08:00AM	Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation (GlobeNewswire)
Aug-15-22 04:05PM	Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results (GlobeNewswire)
Aug-11-22 06:00AM	JDS1, LLC Terminates Proxy Contest at Catalysts 2022 Annual Meeting (Business Wire)
Aug-10-22 12:46PM	Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board (GlobeNewswire)
Aug-03-22 08:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote FOR All of the Companys Nominees on the WHITE Proxy Card (GlobeNewswire)
Aug-01-22 08:30AM	Catalyst Biosciences Publishes New Investor Presentation (GlobeNewswire)
07:30AM	Catalyst Biosciences Announces Support from Largest Single Stockholder (GlobeNewswire)
Jul-22-22 12:21PM	JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders (Business Wire)
Jul-19-22 08:00AM	Catalyst Biosciences Sends Letter to Stockholders (GlobeNewswire)
Jul-14-22 09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-06-22 08:00AM	Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling (GlobeNewswire)
Jun-29-22 08:00AM	Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders (GlobeNewswire) +13.25%
Jun-28-22 09:40AM	Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year? (Zacks) -5.03%
May-26-22 11:03AM	The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup (American City Business Journals) -22.38%
May-23-22 09:57AM	Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex (Benzinga) +234.21%
08:30AM	Catalyst Biosciences Sells Complement Portfolio for $60 Million (GlobeNewswire)
May-09-22 08:30AM	Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results (GlobeNewswire) -11.42%
Apr-08-22 09:57AM	Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely (Simply Wall St.) -7.26%
Mar-31-22 08:00AM	Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-15-22 05:00PM	Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIOs Complement Portfolio in Ophthalmology (GlobeNewswire) +9.50%
Feb-17-22 08:00AM	Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives (GlobeNewswire) +6.40%
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com)
Jan-25-22 08:00AM	Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency (GlobeNewswire) -7.05%
Jan-12-22 12:00PM	Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-20-21 07:51PM	Penny Stocks to Buy Using Technical Analysis for January 2022 (Investopedia)
Dec-11-21 11:59AM	Timothy P. Lynchs Stonepine Capital Portfolio: Top 10 Healthcare Stocks (Insider Monkey)
Nov-22-21 08:00AM	Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-12-21 09:54AM	Catalyst Biosciences Down 40% After Announcing MarzAA Development Halt (Investing.com) -41.84%
09:24AM	What Is Happening With Catalyst Biosciences Shares Today? (Benzinga)
07:00AM	Catalyst Biosciences Announces Change in Corporate Strategy (GlobeNewswire)
Oct-29-21 08:00AM	Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences (GlobeNewswire)
Oct-28-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +5.03%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ye Weiguo	Chief Operating Officer	Jun 10 '26	Option Exercise	0.75	5,000	3,750	705,000	Jun 22 04:02 PM
Ye Weiguo	Chief Operating Officer	Jun 09 '26	Option Exercise	0.75	3,000	2,250	703,000	Jun 22 04:02 PM
Ye Weiguo	Chief Operating Officer	Jun 18 '26	Option Exercise	0.75	3,000	2,250	703,000	Jun 22 04:02 PM
Ye Weiguo	Chief Operating Officer	Jun 10 '26	Sale	6.24	5,000	31,200	700,000	Jun 22 04:02 PM
Ye Weiguo	Chief Operating Officer	Jun 18 '26	Sale	6.35	3,000	19,050	700,000	Jun 22 04:02 PM
Ye Weiguo	Chief Operating Officer	Jun 09 '26	Sale	6.15	3,000	18,450	700,000	Jun 22 04:02 PM
Ye Weiguo	Chief Operating Officer	Jun 11 '26	Option Exercise	0.75	2,800	2,100	702,800	Jun 15 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 11 '26	Sale	6.17	2,800	17,276	700,000	Jun 15 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 09 '26	Option Exercise	0.75	14,500	10,875	714,500	Jun 11 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 10 '26	Option Exercise	0.75	6,418	4,814	706,418	Jun 11 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 09 '26	Sale	6.14	14,500	89,030	700,000	Jun 11 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 10 '26	Sale	6.21	6,418	39,856	700,000	Jun 11 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 04 '26	Option Exercise	0.75	19,575	14,681	719,575	Jun 08 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 05 '26	Option Exercise	0.75	15,401	11,551	715,401	Jun 08 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 04 '26	Sale	6.13	19,575	119,995	700,000	Jun 08 04:01 PM
Ye Weiguo	Chief Operating Officer	Jun 05 '26	Sale	6.40	15,401	98,566	700,000	Jun 08 04:01 PM
Ye Weiguo	Chief Operating Officer	May 26 '26	Option Exercise	0.75	4,000	3,000	704,000	May 27 04:01 PM
Ye Weiguo	Chief Operating Officer	May 22 '26	Option Exercise	0.75	3,500	2,625	703,500	May 27 04:01 PM
Ye Weiguo	Chief Operating Officer	May 26 '26	Sale	6.10	4,000	24,400	700,000	May 27 04:01 PM
Ye Weiguo	Chief Operating Officer	May 22 '26	Sale	6.08	3,500	21,280	700,000	May 27 04:01 PM
Ye Weiguo	Chief Operating Officer	May 21 '26	Option Exercise	0.75	12,820	9,615	712,820	May 22 06:19 PM
Ye Weiguo	Chief Operating Officer	May 20 '26	Option Exercise	0.75	9,400	7,050	709,400	May 22 06:19 PM
Ye Weiguo	Chief Operating Officer	May 21 '26	Sale	6.15	12,820	78,843	700,000	May 22 06:19 PM
Ye Weiguo	Chief Operating Officer	May 20 '26	Sale	6.15	9,400	57,810	700,000	May 22 06:19 PM
Ye Weiguo	Chief Operating Officer	May 19 '26	Option Exercise	0.75	9,120	6,840	709,120	May 20 04:01 PM
Ye Weiguo	Chief Operating Officer	May 18 '26	Option Exercise	0.75	200	150	700,200	May 20 04:01 PM
Ye Weiguo	Chief Operating Officer	May 19 '26	Sale	6.37	9,120	58,094	700,000	May 20 04:01 PM
Ye Weiguo	Chief Operating Officer	May 18 '26	Sale	6.62	200	1,324	700,000	May 20 04:01 PM
Ye Weiguo	Chief Operating Officer	May 14 '26	Option Exercise	0.75	15,580	11,685	715,580	May 18 04:01 PM
Ye Weiguo	Chief Operating Officer	May 15 '26	Option Exercise	0.75	13,100	9,825	713,100	May 18 04:01 PM
Ye Weiguo	Chief Operating Officer	May 14 '26	Sale	6.91	15,580	107,658	700,000	May 18 04:01 PM
Ye Weiguo	Chief Operating Officer	May 15 '26	Sale	6.65	13,100	87,115	700,000	May 18 04:01 PM
Ye Weiguo	Officer	May 13 '26	Proposed Sale	7.07	300,000	2,121,000		May 11 07:10 AM
Luo Ying	Chief Executive Officer	May 06 '26	Sale	8.04	10,136	81,493	2,565,226	May 07 09:58 PM
Luo Ying	Chief Executive Officer	May 05 '26	Sale	8.01	179	1,434	2,575,362	May 07 09:58 PM
Ye Weiguo	Officer	Nov 15 '25	Proposed Sale	8.34	548,000	4,570,320		Nov 13 08:32 PM

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Chief Financial OfficerMr. Thomas W. Eastling M.D.

Chief Operating OfficerMr. Weiguo Ye

Chief Information OfficerMs. Ruoyu Chen

CEODr. Ying Luo Ph.D.

Chief Scientific Officer & DirectorDr. Yue Xiong Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GYRE

Gyre Therapeutics Inc

Upgrade your Finviz experience